Tirzepatide Once Weekly for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many patients treated with GLP-1RAs achieve clinically meaningful weight loss while simultaneously demonstrating improvements in cardiometabolic health.45,46”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [46]
In the citing paper
“with two articles presenting LM outcomes in only a subset of participants from the parent trial (6, 7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Indeed, clinical trials demonstrate substantial weight loss achievable with GLP1Ra-based therapy, ranging from 12-15% over a one-year period for semaglutide (6), to weight losses rivaling what is seen with bariatric surgery for tirzepatide (7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Across body weight and composition outcomes, the greatest magnitude of weight loss was observed in the SURMOUNT (7) and STEP (6) trials, respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“However, the magnitude of the treatment effect on total body mass was nearly two times greater in trials using GLP1Ra-based therapies at dosages indicated primarily for chronic weight management (6, 7, 18, 21, 24) as compared to trials using dosages indicated primarily for diabetes management (17, 19, 20, 22): −10.2 kg (−16.3, −3.9) versus −5.5 kg (−8.7, −2.1), respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
174 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Self-citationRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 1,701–1,800 of 3,704
Zhang, J., Sonnenburg, D., Tricò, D., Kabisch, S., Mari, A., Theis, S., Kemper, M., Pivovarova‐Ramich, O., Rohn, S., & Pfeiffer, A. F. H. (2024) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202300086 · Cited by 4
Molecular design of peptide therapeutics via N-terminal modification
Sürmeli, D., Dinsmore, T. C., Anchukaitis, H. M., Montanari, V., Beinborn, M., & Kumar, K. (2024) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2024.04.011 · Cited by 7
Advances in Drug Treatments for Companion Animal Obesity
Zomer, H. D., & Cooke, P. S. (2024) · Biology · doi:10.3390/biology13050335 · Cited by 10
Alsanea, S., Alkofide, H., Almadi, B., Almohammed, O. A., Alwhaibi, A. M., Alrabiah, Z., & Kalagi, N. A. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.05.009 · Cited by 5
New insights into understanding obesity: from measures to mechanisms
Timpson, N. J., Wade, K. H., Smith, M. L., Goudswaard, L. J., Sattar, N. A., Pournaras, D. J., & Corbin, L. J. (2024) · BMJ Medicine · doi:10.1136/bmjmed-2023-000787 · Cited by 7
Rogers, R. J. (2024) · ACSMʼs Health & Fitness Journal · doi:10.1249/fit.0000000000000972 · Cited by 4
Liraglutide in the management of obesity: real world data (Portugal)
Bello, C., Carvalho, I. R., Martins, A., Martins, A. F., Wessling, A., Macedo, D. D., Martins, D., Fernandes, C. C., & do Rosário, F. S. (2024) · Minerva Endocrinology · doi:10.23736/s2724-6507.24.04161-7 · Cited by 4
Exposure–response modeling for nausea incidence for cotadutide using a Markov modeling approach
Yu, H., Ueckert, S., Zhou, L., Cheng, J. Y., Robertson, D. C., Hansen, L. B., Flor, A., Parker, V., Hamrén, B., & Khan, A. A. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13194 · Cited by 4
“…where dulaglutide indicated overall percentile patients with nausea below 20% across several clinical studies, 30–33 tirzepatide demonstrated a 33.3% proportion at 10 mg dose and 31% at 15 mg dose in participants with obesity, 34 and semaglutide showed a 45% percentile in obesity/NASH studies.”
BackgroundInfluentialWei, L., Lin, Y.-W., Luo, J.-C., Li, Y., Hu, Y., Guo, S., Jiang, Z., Zhao, D., Chen, S.-B., & Huang, Z.-S. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116773 · Cited by 5
Anderson, J. J., Deo, S. V., Welsh, P. I., Mackay, D., Ho, F. K. W., Ferguson, L. D., Celis-Morales, C. A., Gill, J. M. R., Pell, J. P., & Sattar, N. A. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15949 · Cited by 9
Recent Trends in Peptide Drug Discovery and Development
Madge, H. Y. R., & Muttenthaler, M. (2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837674541-00023 · Cited by 6
Salerno, M. L. D. S., Leães, C. G. S., da Silva, P. B. E., Weston, A. C., Carli, L. A. D., & Pereira‐Lima, J. F. S. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07557-y · Cited by 5
“…of obesity with a body mass index (BMI) ≥ 40 kg/m 2 or ≥ 35 with at least one obesity-related comorbidity, resulting in superior and sustained long-term weight loss compared to currently available clinical treatments [4, 5], even though new anti-obesity drugs in development are very promising [6].”
Chandra, A. A., Espiche, C., Maliha, M., Virani, S. S., Blumenthal, R. S., Rodríguez, F., Wong, N. D., Gulati, M., Slipczuk, L. N., & Shapiro, M. D. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100919 · Cited by 7
“Trials such as SURMOUNT and PIONEER have shown GLP-1 RA can lead to significant reductions in systolic blood pressure, primarily through weight loss [55,58,59].”
Finks, S. W., Benavides, D., Martin, A. G., & Carmon, A. S. (2025) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.2071 · Cited by 5
“4,11,14 However, in-depth pharmacist involvement (i.e., weekly visits with advice for specific safety concerns, shared decision-making, de-escalation of dose, etc.) influencing discontinuation rates and improved outcomes should not be overlooked.”
InfluentialNPA7: A Dual Receptor Activating Peptide That Inhibits Cardiac Oxidative Stress
Ma, X., Malsawmzuali, J., Moroni, D., Ma, X., Zheng, Y., Pan, S., Wang, Y., Sangaralingham, S. J., & Burnett, J. C. (2025) · Hypertension · doi:10.1161/hypertensionaha.124.23579 · Cited by 5
“44 While NPA7 demonstrates therapeutic potential in our experimental studies, several challenges must be addressed for its clinical application.”
Effects of antidiabetic agents on lipid metabolism of skeletal muscle: A narrative review
Xu, M., Lv, D., Wei, H., Li, Z., Jin, S., Liu, Q., Zhang, Y., & Liu, Y. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16189 · Cited by 5
“102,103 Clinical trial revealed that tirzepatide treatment resulted in greater improvements in insulin sensitivity compared to semaglutide.”
Antiobesity Medications in Patients With Heart Failure
Hussani, S. F., Nguyen, K., Yu, K. M., Sinha, D., & Vest, A. R. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2024.10.018 · Cited by 5
Safety and Efficacy of Liraglutide and Semaglutide in Kidney Transplant Recipients
Kahwaji, J. M., Hashmi, S., Parke, C. Y., et al. (2025) · Kidney360 · doi:10.34067/kid.0000000706 · Cited by 4
Wang, S., Schwartz, P. F., & Mancuso, J. P. (2025) · BMC Medical Research Methodology · doi:10.1186/s12874-025-02494-5 · Cited by 5
“When the trial duration is long and rescue therapy is prohibited throughout the trial [2, 11, 12, 17], the dropout rate in placebo group can be higher if participants in the active Fig.”
Lazarus, E. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100170 · Cited by 9
“Consistent with other trials evaluating antiobesity treatments [47, 49,50], the COR trials enrolled predominantly female populations (COR-I, 85 %; COR-II, 84.6 %; COR-DM, 58 %; COR-BMOD, 89”
InfluentialSlattery, J. D., Rambousek, J. R., Tsui, E. W., Honeycutt, M. K., Goldberg, M., Graham, J. L., Wietecha, T., Wolden‐Hanson, T., Williams, A. L., O’Brien, K. D., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1503096 · Cited by 5
“Despite the considerable improvements that have been made with respect to weight loss, these treatments are still associated with adverse gastrointestinal side effects (10), leading, in some cases, to the discontinuation of the drug in up to 7.1% of participants (10).”
InfluentialGrady, M., Holt, E., Cameron, H., & Edelman, S. V. (2025) · Scientific Reports · doi:10.1038/s41598-025-93605-1 · Cited by 4
Coon, S. A., White, R. T., Pagnozzi, D., & Cowart, K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16349 · Cited by 6
“6 A recent post hoc analysis of the SURMOUNT-1 trial also found that tirzepatide significantly reduced the 10-year predicted risk of developing T2D as compared with placebo.”
Role of Microneedles for Improved Treatment of Obesity: Progress and Challenges
Chilamakuri, S. N., Manasa, N., Thalla, M., Ravichandiran, V., Lee, Y., Cho, S. M., Jung, H., & Natesan, S. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c01115 · Cited by 5
Pharmacotherapy for the management of overweight and obesity?
Forner, P. M., & HOCKING, S. L. (2025) · Australian Journal of General Practice · doi:10.31128/ajgp-09-24-7411 · Cited by 8
Yoo, S., Yoo, E.-S., Kim, J. I., & Sohn, J. (2025) · Endocrinology and Metabolism · doi:10.3803/enm.2024.2185 · Cited by 4
“This drug has been shown to cause significant body weight loss and is already in clinical use [27].”
Smith, L. A., Craven, D. M., Ho, A. N., Glenny, E. M., Rezeli, E. T., Carson, M. S., Paules, E. M., Fay, M., Cozzo, A. J., Hursting, S. D., et al. (2025) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-24-0514 · Cited by 8
Odoardo, L. A. F. D., Zucchetti, O., Sciatti, E., D’Isa, S., D’Elia, E., & Senni, M. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suaf032 · Cited by 6
Fatal, Fulminant, Necrotizing Pancreatitis Associated With Recent Tirzepatide Initiation
Grennan, K., Borg, C., Meneley, A., Janitz, T. M., SHUMAN, M., & Venegas, C. (2025) · JCEM Case Reports · doi:10.1210/jcemcr/luaf087 · Cited by 5
“It is also approved and often used for its significant weight loss benefits in patients with obesity without diabetes [2].”
Anthropometric Trajectories and Dietary Compliance During a Personalized Ketogenic Program
García-Gorrita, C., Soriano, J. M., Merino-Torres, J. F., & Onofre, N. S. (2025) · Nutrients · doi:10.3390/nu17091475 · Cited by 4
Humięcka, M., Sawicka, A., Kędzierska, K., Kotowicz, M., Koczkodaj, M., Jaworski, P., Binda, A., Tarnowski, W., & Jankowski, P. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119232 · Cited by 4
Access to GLP-1s: Where Do Employers Fit in?
Imboden, M. T. (2025) · American Journal of Health Promotion · doi:10.1177/08901171251335507 · Cited by 4
The Critical Role of Lifestyle With the Use of Contemporary Obesity Management Medications
Rogers, R. J., Hosking, M., Burridge, K., Orr, M., & Bantham, A. (2025) · American Journal of Health Promotion · doi:10.1177/08901171251335507c · Cited by 4
“4,5 While originally developed for the treatment of type 2 diabetes, these agents have demonstrated signi fi cant improvements in body weight beyond what has been traditionally observed with lifestyle (dietary and exercise) strategies alone, 6 with magnitudes of body weight lost doubling that…”
Treating obesity to optimize women’s health outcomes
Rubino, D., & Schon, S. B. (2025) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002595 · Cited by 4
Hassan, M. G., Hassan, D., & Hassan, G. A. (2025) · The Journal of the American Dental Association · doi:10.1016/j.adaj.2025.05.007 · Cited by 5
Holtrop, J. S., Tietbohl, C. K., Perreault, L., Connelly, L., Smith, P. C., & Williams, J. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1584799 · Cited by 7
Behandlungsstrategien bei diabetischer Nephropathie – Update 2022
Schork, A., & Artunç, F. (2022) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1911-0201 · Cited by 4
Patel, P. N., Fox, C. K., Bensignor, M. O., & Bomberg, E. M. (2022) · JCEM Case Reports · doi:10.1210/jcemcr/luac038 · Cited by 4
“…significant and durable weight loss compared to AOMs, many patients unfortunately experience significant weight gain following MBS (often requiring AOMs in the post-surgical setting), and more recently developed AOMs are, on average, far more effective compared to those previously available [6–8].”
BackgroundMethodResultInfluentialSuits, A., Gudoor, R., & Shubrook, J. H. (2023) · Diabetology · doi:10.3390/diabetology4010011 · Cited by 5
“The new dual-incretin tirzepatide has also been demonstrated to provide significant HbA1c reductions and substantial weight loss as outlined in the SURPASS and SURMOUNT trials [40,41].”
BackgroundCircadian control of white and brown adipose tissues
Yue, K., Rensen, P. C. N., & Kooijman, S. (2023) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2023.102056 · Cited by 5
Partial Meal Replacement for Weight Loss after Stroke: Results of a Pilot Clinical Trial
Dearborn, J. L., Viscoli, C. M., Amin, H., Lovelett, L., Rivera, J., Gull, A., & Kernan, W. N. (2023) · Cerebrovascular Diseases · doi:10.1159/000530996 · Cited by 6
“Recent trials of glucagon-like peptide receptor agonist therapy and dual glucagon-like peptide1/glucose-dependent insulinotropic polypeptide receptor agonist therapy demonstrate greater weight loss than is typically achieved with behavioral therapy alone [23 – 25].”
MethodHenney, A. E., & Wilding, J. P. H. (2023) · Medicine · doi:10.1016/j.mpmed.2023.04.009 · Cited by 4
Pérez‐Martínez, P., Gómez‐Huelgas, R., Escribano, P. P. C., Arévalo‐Lorido, J. C., Soto, M. I. P., & Carretero‐Gómez, J. (2023) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2023.07.005 · Cited by 7
Tirzepatide for the Treatment of Heart Failure in Type 2 Diabetes Mellitus: (SUR)PASS, or Not?
Patoulias, D., Dimosiari, A., & Fragakis, N. (2023) · Future Cardiology · doi:10.2217/fca-2022-0112 · Cited by 4
Sridhar, A., Khan, D., Flatt, P. R., Moffett, R. C., & Irwin, N. (2023) · Peptides · doi:10.1016/j.peptides.2023.171093 · Cited by 6
Block, T. J., & Cooper, M. E. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104178 · Cited by 5
Aberle, J., Lautenbach, A., Meyhöfer, S., Meyhöfer, S. M., Menzen, M., Selig, L., Mai, K., & Blüher, M. (2023) · Diabetologie und Stoffwechsel · doi:10.1055/a-2076-0105 · Cited by 6
“63%), verlo-ren mindestens 20 % ihres Körpergewichts, verglichen mit nur 1,3% unter Placebo [24].”
Tu, S., Chen, J. Z., Singh, S. R. K., Maraboyina, S., Gökden, N., Hsu, P.-C., & Langford, T. (2024) · Cancers · doi:10.3390/cancers16030624 · Cited by 6
“One loses 20% or more of one’s weight (vs. 3% on placebo, SURMOUNT-1 trial) on tirzepatide [74].”
BackgroundWeight-centric prevention of cancer
Añazco, D., Acosta, A. J., Cathcart-Rake, E. J., D’Andre, S. D., & Hurtado, M. D. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100106 · Cited by 5
“Newer glucagon-like peptide-1 (GLP-1) receptor agonists (i. e., semaglutide) and glucose-dependent insulinotropic polypeptide (GIP) co-agonists (i.e., tirzepatide) have showed significantly superior weight loss outcomes in comparison to other antiobesity medications [77,78].”
ResultSamuels, J. M., Patel, M. B., Roumie, C. L., Self, W. H., Funk, L. M., Spann, M. D., & Niswender, K. D. (2024) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2024.08.041 · Cited by 4
“Several medications for weight loss were approved by the Food and Drug Administration (FDA) in the last 5 years, including the latest generation of glucagon-like peptide 1 receptor agonists (GLP1RA) that achieve 15%–20% total weight loss (TWL) [1,2].”
Discordance between gut-derived appetite hormones and energy intake in humansPreprint
Hengist, A., Sciarrillo, C. M., Guo, J., Walter, M. F., & Hall, K. D. (2023) · medRxiv · doi:10.1101/2023.05.10.23289718 · Cited by 6
First-Time Prescribing of GLP-1 Receptor Agonists from 2018-2023: A Descriptive AnalysisPreprint
Rodriguez, P. J., Gratzl, S., Cartwright, B. M. G., Brar, R., Gluckman, T. J., & Stucky, N. L. (2023) · medRxiv · doi:10.1101/2023.08.22.23294277 · Cited by 5
Dahir, N. S., Gui, Y., Wu, Y., Sweeney, P. R., Williams, S. Y., Gimenez, L. E., Sawyer, T. K., Joy, S. T., Mapp, A. K., & Cone, R. D. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.05.570114 · Cited by 4
“This diabetes drug acts as a dual agonist for GLP1R and the glucose-dependent insulinotropic polypeptide (GIP) in humans 18,19 .”
Griffiths, A., Shannon, O. M., Spreckley, M., Austin, K., Fallows, E., Clare, K., Ells, L. J., & Matu, J. (2025) · medRxiv · doi:10.64898/2025.12.11.25342052 · Cited by 4
Leonhard, A. G., Josey, K., Castaneda, J. M., Chee, M., Duan, K. I., Nadeem, H., Plumley, R., Triplette, M., Smith, N. L., Au, D. H., et al. (2026) · Annals of the American Thoracic Society · doi:10.1093/annalsats/aaoag047 · Cited by 3
Tirzepatide—New Evidence for the Treatment of Obesity From China
Jia, W., Xiao, J., & Chan, J. C. N. (2024) · JAMA · doi:10.1001/jama.2024.9104 · Cited by 3
Obesogenic Medication Use in End‐Stage Kidney Disease and Association With Transplant Listing
Orandi, B. J., Li, Y., Seckin, T., Bae, S., Lonze, B. E., Ren‐Fielding, C. J., Lofton, H. F., Gujral, A., Segev, D. L., & McAdams‐DeMarco, M. (2024) · Clinical Transplantation · doi:10.1111/ctr.15414 · Cited by 4
“With the advent of nutrient stimulating hormones (e.g., glucagon-like peptide-1 agonists, gastric inhibitory peptide), significant weight loss can be achieved; however, these medications can be prohibitively expensive, side effects may be limiting for some, and drug shortages are common [38, 39].”
Baran, K., Jankowska, M., Jańczyk, N., Mędrysa, K., Pokrzepa, J. J., Presak, M., Blecharz, G., Szwech, J., Winkowska, A., & Machalica, J. (2024) · Quality in Sport · doi:10.12775/qs.2024.30.56469 · Cited by 4
Human Sports Drug Testing: Analytical Challenges and Solutions
Thevis, M., Walpurgis, K., & Thomas, A. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c00339 · Cited by 4
Thiara, D. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.0237 · Cited by 3
Cardiometabolic health and ASCVD primary prevention: time to take actions
Liu, J. (2025) · npj Cardiovascular Health · doi:10.1038/s44325-025-00050-0 · Cited by 3
Zhao, L., Tao, F., Cheng, Z., Lu, Y., Liu, M. R., Chen, H., Zhang, M., Yang, Y., Song, X. H., Sun, Y., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16439 · Cited by 3
Research Progress of Traditional Chinese Medicine in Adjuvant Treatment of Type 1 Diabetes
Luo, J. F., Hu, F., Jia, Z., Zhu, X., Zhou, Y., Hu, C., Yu, L., & Chen, Z. (2025) · Phytotherapy Research · doi:10.1002/ptr.8514 · Cited by 3
The history of the pharmacotherapy of obesity
Berkovskaya, M. A., Gurova, O. Y., Surkova, E. V., & Fadeev, V. V. (2025) · Problems of Endocrinology · doi:10.14341/probl13469 · Cited by 5
“При-мечательно, что в отличие от предшественников (лира-глутид, семаглутид) терапия тирзепатидом сопровожда-лась продолжающимся снижением массы тела в течение всего периода испытания (72 недели) без выхода на «пла-то» [54].”
Ouyang, Y., Xiang, X., Hu, X., Chu, X., Tang, W., & Feng, W. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1580159 · Cited by 3
“This concept is consistent with tirzepatide trials (a GLP-1/GIP dual agonist), where activation of the GIP receptor overcame reduced ef fi cacy in treatment-resistant populations (28).”
Registered clinical trials targeting type 2 diabetes remission with pharmacological interventions
Shoung, N., Carette, C., Rassy, N., Phan, A., Greenfield, J. R., Hu, F. B., Rives‐Lange, C., & Czernichow, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-00080-9 · Cited by 5
“As previous research has shown that achieving weight loss earlier in the course of T2D increases the chances of achieving remission 28 the use of GLP-1 receptor agonists and newer dual agonists that include GIP analogues may have a role 29,30 .”
Contractile effects of retatrutide in isolated mouse atrial preparations
Neumann, J., Ahlrep, U., Hofmann, B., & Gergs, U. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04335-0 · Cited by 3
Hunter, T. M., Hankosky, E. R., Meeks, A., Liao, B., Ward, J., Huang, A., & Chinthammit, C. (2025) · Clinical Therapeutics · doi:10.1016/j.clinthera.2025.05.003 · Cited by 3
Beyond the Average: Trends in Extreme Sodium Intake in the U.S. Population, 2003–2018
Chen, Y., Wang, J., Leonberg, K. E., Chui, K. K. H., Ausman, L. M., & Naumova, E. N. (2025) · Nutrients · doi:10.3390/nu17121975 · Cited by 4
Time to screen: rationale and roadmap for HFpEF screening in individuals with obesity
Achten, A., Peeters, L., Verkoulen, G. H. J. M., Weerts, J., Knackstedt, C., Boerma, E.-J. G., van Empel, V. P. M., & Wijk, S. S. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10540-z · Cited by 5
Gabery, S., Glendorf, T., Ballarín-González, B., Pedersen, K., Kruse, T., Raun, K., & Kuhre, R. E. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123845 · Cited by 4
GPs’ perspectives on GLP-1RAs for obesity management: a qualitative study in England
Keating, S., Wild, C. E. K., Scragg, J. H., Dixon, S., Treadwell, J. S., Hinton, L., & Jebb, S. A. (2025) · British Journal of General Practice · doi:10.3399/bjgp.2025.0065 · Cited by 6
Wang, Y., Chen, J., He, Y., Lv, Y., Guo, H., Zheng, Q., & Li, L. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16599 · Cited by 5
Ramirez, S., Yang, R., Habibovic, M., Kennedy, S., Bennett, J. P., Shepherd, J., Thomas, D. M., & Heymsfield, S. B. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01842-1 · Cited by 5
Neurobeachin ( NBEA ) is a novel gene associated with GLP ‐1 receptor agonist associated weight loss
Mariam, A., Breeyear, J. H., Daniels, N. J., Pantalone, K. M., Griebeler, M. L., Motsinger‐Reif, A. A., & Rotroff, D. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16612 · Cited by 4
Cercato, C., Stumpf, M. A. M., Freire, G. N. D. C., Kawahara, E. Z., Fernandes, A. E., de Melo, M. E., & Mancini, M. C. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01842-1 · Cited by 4
Wang, J., Kang, J., Peng, T., Chen, H., Chen, S., & Lee, M. (2025) · Clinical Obesity · doi:10.1111/cob.70036 · Cited by 5
“Following a systematic search, 11 studies were assessed for eligibility [9, 10, 19–27].”
InfluentialJanuary, S. E., Fester, K. A., Escamilla, J. E., & Cano, M. (2025) · Clinical Transplantation · doi:10.1111/ctr.70246 · Cited by 3
“[13] compared to those who received GLP-1 RA.”
Leith, A., Harrison, L., Fernandes, J. D. D. R., Hagelund, L. M., Lübker, C., & Capucci, S. (2025) · Journal of health economics and outcomes research · doi:10.36469/jheor.2025.141081 · Cited by 5
Advancing Person-Centered Care in the New Era of Obesity Treatment
Schumacher, L. M., Brocq, S. L., Wharton, S., Fox, C. K., Schur, E. A., Sumithran, P., & Ard, J. D. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09742-w · Cited by 4
“52–56 While the flurry of attention on newer medications may seem to suggest that pharmaco-therapy will or should be the treatment of choice for all patients, this is not necessarily the case.”
Self-citationLarsen, A. T., Melander, S. A., Mohamed, K. E., Petersen, E. A., Benmarce, M., Karsdal, M. A., & Henriksen, K. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118388 · Cited by 3
Berković, M. C., Ružić, L., Cigrovski, V., & Strollo, F. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i9.109123 · Cited by 10
Schumacher, L. M., & Sarwer, D. B. (2025) · Plastic & Reconstructive Surgery Global Open · doi:10.1097/gox.0000000000007085 · Cited by 3
“16 23 Consequently, these medications have garnered significant media attention and have quickly made their way into the awareness of many Americans.”
Precision Prevention, Diagnostics, and Treatment of Obesity: Pipedream or Reality?
Woolf, E. K., Diktas, H. E., Acosta, A. J., Apolzan, J. W., Ard, J. D., Boyle, K. E., Gilbert, J. A., Katzmarzyk, P. T., Laurienti, P. J., Lobstein, T., et al. (2025) · Obesity · doi:10.1002/oby.70015 · Cited by 8
“Furthermore, only ~3%–4% had no weight loss or weight gain [85].”
Overweight and obesity in metabolic syndrome
Nedogoda, S. V., & Васильевна, Ц. О. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6535 · Cited by 5
Ashlaw, E. F., Elfers, C., Chichura, K. S., Miranda, I. C., McGivney, A., Chepurny, O. G., Holz, G. G., Mullins, G., den Hartigh, L. J., Liu, Y., et al. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156414 · Cited by 5
“It is now clear that GLP-1R/GIPR dual agonists have led to improved patient outcomes, exemplified by tirzepatide (TZP) [3,37].”
Pedigo, J., Eastman, K. A. S., & Bandarian, V. (2025) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.5c00152 · Cited by 3
Lifestyle interventions for hypertension management in primary care: a narrative review
Han, B., Lee, G. B., Yoon, J., & Kim, Y. (2025) · Ewha Medical Journal · doi:10.12771/emj.2025.00850 · Cited by 11
“When lifestyle interventions alone are insufficient, pharmacologic options (e.g., GLP-1 receptor agonists) or bariatric surgery may be considered [37].”
Kurnia, D., Dharsono, H. D. A., Takaya, A., Padilah, R., & Apriyanti, E. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s554704 · Cited by 3
Advances in Pharmacotherapies for Obesity-Related HFpEF: A Comprehensive Review
Wu, Y., Song, M., Chen, X., Chen, W., Wu, M., & Lin, L. (2025) · Current Heart Failure Reports · doi:10.1007/s11897-025-00722-z · Cited by 3
“This dual action contributes to its superior efficacy in weight reduction, with clinical trials showing a mean weight loss of 20.9% with tirz - epatide compared to 14.9% with semaglutide in patients with obesity [ 53 , 54 ].”
InfluentialAcute Deep Vein Thrombosis in the Setting of Tirzepatide Use: A Case Highlighting Emerging Concerns
Sonavane, K., Agrawal, G., Agarwal, B., Parsi, S., Ponnam, H. K. C., & Shirsat, P. D. (2025) · JCEM Case Reports · doi:10.1210/jcemcr/luaf248 · Cited by 3
“SURMOUNT-1 trial reported substantial, sustained weight loss in individuals with obesity treated with tirzepatide [2].”
Raza, S. S., Zakir, Z., Hashmat, A., Awan, S. K., & Varrassi, G. (2025) · Cureus · doi:10.7759/cureus.96739 · Cited by 8
“The third pathway uses incretin biology to reduce appetite, slow gastric emptying, and improve metabolic control (liraglutide, semaglutide, and tirzepatide) [1-6, 9”
InfluentialAnti‐Obesity Effects Exerted by Achyranthes bidentata Polysaccharides in Diet‐Induced Obese Mice
Li, S., Zhang, W., Liu, Y., Shi, W., Zhang, Y., Li, X., Jin, L., Cui, M., Li, Y., & Chen, W. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.71185 · Cited by 3
Machine learning-guided optimization of triple agonist peptide therapeutics for metabolic disease
Wong, A., Guduri, S., Chen, T.-Y., & Patel, K. (2025) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2025.1687617 · Cited by 4
“The clinical development of retatrutide, a triple agonist targeting GCGR, GLP1R, and GIPR, has further demonstrated the potential of multi-target approaches, with Phase 2 results showing 24.2% weight reduction at 48 weeks (Jastreboff et al., 2022).”
InfluentialHeinberg, L. J., Lee, A. M., Foster, G. D., DiVita, A. L., Allman, M., Rotroff, D. M., Dargham, C. B., & Cardel, M. I. (2025) · Obesity · doi:10.1002/oby.70056 · Cited by 3
Gelfand, S. T., Tveit, M., & Simon, J. A. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100233 · Cited by 8
“…of well-being [53,54] Aesthetic side effects such as “ Ozempic face ” [67] Increased physical activity and adherence to exercise [56,57] Fatigue [68] Improved sleep [65,66] Weight regain [69] Improved erectile function and female arousal response [10 – 12,72] Stigmatizing attitudes towards…”
A metabolic comparison of GIPR agonism versus GIPR antagonism in male mice
Davies, I., Turland, A., Tran, H. D., Wong, C., Cahn, O., Dunsterville, C., Sun, Y., Xiao, Y., Murphy, K. G., Bloom, S. R., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70300 · Cited by 3
“11,12 While previous studies have described metabolic consequences of either GIPR agonist or antagonist treatment in isolation, 2,6,7,13,14 an in-depth side-by-side comparison of each approach of GIPR targeting has yet to be conducted.”
Johnson, H. H., Clift, A. K., Reisel, D., & Huang, D. R. (2026) · Journal of Medical Internet Research · doi:10.2196/83718 · Cited by 6
“The SURMOUNT-1 trial reported mean weight reductions of 15% to 20.9% at 72 weeks, significantly surpassing previous pharmacotherapies [4].”
InfluentialZheng, Y., Guo, Z., Jeong, E., Xu, S., Samuels, J. M., Dawwas, G. K., Tao, R., Srivastava, G., Chen, Y., & Yu, D. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.113041 · Cited by 3
Rahman, M. H., Selim, S., Afsana, F., Hoque, M. A., Saifuddin, M., Alam, M. S., Sharifuzzaman, M., Tareq, M. A. H., Hasan, M. N., Kamrul-Hasan, A. B. M., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70343 · Cited by 5
“38,39 21 The shorter, 12-week observation period in the present real-world study captures TABLE 1 Baseline (pre-Ramadan) characteristics of the study participants.”
Metadata
- Authors
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A.
- Affiliations
- Eli Lilly (United States) (US)
- From the Section of Endocrinology and Metabolism, Department of Medicine, and the Section of Pediatric Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (A.M.J.); the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York (L.J.A.); Eli Lilly, Indianapolis (N.N.A., S.Z., B.L., M.C.B., A.S.); McMaster University, Hamilton, and York University and Wharton Weight Management Clinic, Toronto — all in Ontario, Canada (S.W.); Intend Research, Norman, OK (L.C.); Centro Paulista De Investigação Clínica (Cepic), Sao Paulo (B.A.); and Tokyo-Eki Center-Building Clinic, Tokyo (A.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-21
- Volume
- 387
- Issue
- 3
- Pages
- 205-216
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281934192
- Semantic Scholar
- 3fb03384cc726ebd9d08c76482e6edf35502d0c7
- Cited by
- 3,838
- References
- 28
- Citations by year
- 2026: 1279 · 2025: 1067 · 2024: 776 · 2023: 562 · 2022: 149
- FWCI
- 382.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- tirzepatide, obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dose escalation, body mass index, weight-related comorbidities, treatment discontinuation, treatment-emergent adverse events, drug safety, subcutaneous administration
- MeSH terms
- Tirzepatide, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.